The massive dilution to existing holders (to ~10.5%) is the dominant financial fact. The LOI is non-binding and subject to multiple conditions including Nasdaq change-of-control review and stockholder approval. Monitor for definitive agreements, a fairness opinion, and Nasdaq's decision on initial listing under Rule 5110(a). The REBOOT transactions are not a condition to closing and may be completed separately or not at all.
Price Chart
Executive Summary
DataMEDS AI entered a non-binding second amended and restated letter of intent to acquire QLPM intellectual property from EOS and Scilex, expand its PharmacyChain license with Datavault AI, acquire a controlling interest in Tollo Health/HLH, and license REBOOT Health AI's IP. The transaction would issue ~89.5% of MEDS common stock to the counterparties, massively diluting existing public holders to ~10.5%. The LOI is non-binding and subject to definitive agreements, due diligence, stockholder approval, Nasdaq change-of-control review, and a liability threshold of no more than $2 million.
Key Facts
- Existing public stockholders would be diluted to approximately 10.5% post-closing, with counterparties owning 89.5%.
- Post-closing ownership: EOS 14.9%, Scilex 14.9%, Datavault 19.9%, Fortitude 5%, HBA/THI 24.9%, REBOOT 9.9%.
- The LOI is non-binding; definitive agreements, due diligence, fairness opinion, stockholder approval, and Nasdaq change-of-control review are required.
- Maximum permitted indebtedness and liability threshold of $2,000,000 as a condition to closing.
- A potential concurrent minimum $2 million investment from Dawson James investors is contemplated.
- REBOOT receives a 6% royalty on adjusted net revenue; EOS and Scilex each receive 5% gross revenue royalties on their respective QLPM portfolios.
- Six-month lock-up on Acquisition Stock for all counterparties, with an exception for EOS distributions to its stockholders.
- Gerald Commissiong (CEO of Tollo Health) appointed Interim Co-CEO of MEDS; four new board designees from EOS, Scilex, Datavault, and HBA.
- Market cap is $11 million; the transaction is expected to close in Q4 2026.
- The LOI includes exclusivity provisions through November 30, 2026, with a 30-day due diligence period for MEDS to terminate.
Financial Impact
Existing public stockholders diluted from 100% to ~10.5% of the company. The transaction contemplates a minimum $2 million investment and a liability threshold of $2 million. No deal value or per-share price is stated.
Risk Factors
- Massive dilution: existing public stockholders would retain only ~10.5% of the company post-closing.
- The LOI is non-binding and the transaction may not close; it requires definitive agreements, due diligence, fairness opinion, stockholder approval, and Nasdaq approval.
- Nasdaq change-of-control review under Listing Rule 5110(a) could result in delisting or additional listing requirements.
- The company has outstanding liabilities that must be reduced to no more than $2 million as a condition to closing.
- Related-party conflicts: Gerald Commissiong is Interim Co-CEO of MEDS, CEO of Tollo Health, and sole owner of Fortitude Advisors; Nathaniel Bradley is CEO of both Datavault AI and EOS.
- The REBOOT transactions are not a condition to closing and may not be completed, creating uncertainty about the full IP portfolio.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-048573 |
| Exhibit: ex99-1.htm | 0001493152-26-048573 |
| Document: form8-k.htm | 0001493152-26-048573 |
| Document: 0001493152-26-048573-index-headers.html | 0001493152-26-048573 |
| Document: 0001493152-26-048573-index.html | 0001493152-26-048573 |
| Document: 0001493152-26-048573.txt | 0001493152-26-048573 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $2.15 | awaiting T+20 | — | $2.06 (+4.19%) |
Oct 20, 2026 7d ago | 8-K | $2.75 | awaiting T+20 | — | $2.06 (−25.09%) |
Oct 16, 2026 11d ago | 8-K | $2.67 | awaiting T+20 | — | $2.06 (−22.85%) |
Oct 13, 2026 14d ago | 8-K | $2.85 | awaiting T+20 | — | $2.06 (−27.72%) |
Sep 17, 2026 5w ago | 8-K | $3.76 $2.63 | ▼ −30.05% | ▼ −30.26% | $2.06 (−45.21%) |
Sep 16, 2026 5w ago | 8-K | $4.64 $2.85 | ▼ −38.58% | ▼ −39.78% | $2.06 (−55.60%) |
Aug 18, 2026 10w ago | 8-K | $1.38 $6.07 | ▼ −339.86% | ▼ −341.60% | $2.06 (−49.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers